Skip to Content

1,417 Results Found

  • Article
  • Open Access
3 Citations
3,516 Views
26 Pages

Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells

  • Guillaume Gerez,
  • Jerome Martinez,
  • Christophe Steinbrugger,
  • Sandra Bouanich and ,
  • Johanna Dimino,
  • Corine Piegay,
  • Maxime Combe,
  • Franck Berthier and
  • Soizic Daniel
  • + 4 authors+ 0 author

24 August 2022

SARS-CoV-2 receptor-binding domain (RBD) is a major target for the development of diagnostics, vaccines and therapeutics directed against COVID-19. Important efforts have been dedicated to the rapid and efficient production of recombinant RBD protein...

(This article belongs to the Special Issue Recombinant Enzymes/Proteins in Biotechnology)
  • Article
  • Open Access
1 Citations
1,253 Views
19 Pages

21 October 2025

The SARS-CoV-2 spike protein, through its receptor binding domain (S1-RBD), binds to the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell membrane, leading to viral infection. Several mutations in S1-RBD in SARS-CoV-2 variants are kno...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
2 Citations
2,578 Views
15 Pages

Tracking Immunity: An Increased Number of COVID-19 Boosters Increases the Longevity of Anti-RBD and Anti-RBD-Neutralizing Antibodies

  • Ching-Wen Hou,
  • Stacy Williams,
  • Veronica Boyle,
  • Alexa Roeder and ,
  • Bradley Bobbett,
  • Izamar Garcia,
  • Giavanna Caruth,
  • Mitch Magee,
  • Yunro Chung and
  • Vel Murugan
  • + 7 authors+ 2 authors

12 January 2025

Background/Objectives: Since the World Health Organization declared COVID-19 a pandemic in March 2020, the virus has caused multiple waves of infection globally. Arizona State University (ASU), the largest four-year university in the United States, o...

(This article belongs to the Special Issue Understanding Immune Responses to COVID-19 Vaccines)
  • Article
  • Open Access
15 Citations
4,105 Views
25 Pages

3 September 2022

The receptor-binding domain (RBD) is the essential part in the Spike-protein (S-protein) of SARS-CoV-2 virus that directly binds to the human ACE2 receptor, making it a key target for many vaccines and therapies. Therefore, any mutations at this doma...

(This article belongs to the Collection Feature Papers in “Molecular Biology”)
  • Article
  • Open Access
9 Citations
3,950 Views
11 Pages

Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response

  • Ting-Wei Lin,
  • Ping-Han Huang,
  • Bo-Hung Liao,
  • Tai-Ling Chao and ,
  • Ya-Min Tsai,
  • Shih-Chung Chang,
  • Sui-Yuan Chang and
  • Hui-Wen Chen
  • + 3 authors+ 0 author

30 October 2022

Recombinant proteins are essential in the development of subunit vaccines. In the design of many recombinant proteins, polyhistidine residues are added to the N- or C-termini of target sequences to facilitate purification. However, whether the additi...

  • Article
  • Open Access
22 Citations
5,506 Views
16 Pages

Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice

  • Mariya B. Borgoyakova,
  • Larisa I. Karpenko,
  • Andrey P. Rudometov,
  • Ekaterina A. Volosnikova and ,
  • Iuliia A. Merkuleva,
  • Ekaterina V. Starostina,
  • Alexey M. Zadorozhny,
  • Anastasiya A. Isaeva,
  • Valentina S. Nesmeyanova and
  • Alexander A. Ilyichev
  • + 16 authors+ 11 authors

16 February 2022

Despite the fact that a range of vaccines against COVID-19 have already been created and are used for mass vaccination, the development of effective, safe, technological, and affordable vaccines continues. We have designed a vaccine that combines the...

(This article belongs to the Special Issue Molecular Mechanisms of Pathogenesis, Prevention, and Therapy of COVID-19: Summarizing the Results of 2021)
  • Article
  • Open Access
35 Citations
5,110 Views
15 Pages

25 August 2021

The receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mediates the viral–host interaction and is a target for most neutralizing antibodies. Nevertheless, SARS-CoV-2 RBD mutations pose a threat due to their...

  • Article
  • Open Access
2 Citations
2,670 Views
21 Pages

GWAS by Subtraction to Disentangle RBD Genetic Background from α-Synucleinopathies

  • Andrea Gaudio,
  • Fabio Gotta,
  • Clarissa Ponti,
  • Alessandro Geroldi and ,
  • Andrea La Barbera and
  • Paola Mandich
  • + 1 author+ 0 author

Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by loss of muscle atonia and abnormal behaviors occurring during REM sleep. Idiopathic RBD (iRBD) is recognized as the strongest prodromal hallmark of α-synucl...

(This article belongs to the Section Molecular Genetics and Genomics)
  • Article
  • Open Access
20 Citations
5,968 Views
10 Pages

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2

  • Yi-Sheng Sun,
  • Jing-Jing Zhou,
  • Han-Ping Zhu,
  • Fang Xu and ,
  • Wen-Bin Zhao,
  • Hang-Jing Lu,
  • Zhen Wang,
  • Shu-Qing Chen,
  • Ping-Ping Yao and
  • Zhan Zhou
  • + 6 authors+ 1 author

26 September 2021

The novel coronavirus pneumonia (COVID-19) pandemic is a great threat to human society and now is still spreading. Although several vaccines have been authorized for emergency use, only one recombinant subunit vaccine has been permitted for widesprea...

(This article belongs to the Collection Coronaviruses)
  • Article
  • Open Access
9 Citations
3,097 Views
12 Pages

A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity

  • Qiaoqiao Qu,
  • Pengfei Hao,
  • Wang Xu,
  • Letian Li and ,
  • Yuhang Jiang,
  • Zhiqiang Xu,
  • Jing Chen,
  • Zihan Gao,
  • Zhaoxia Pang and
  • Chang Li
  • + 6 authors+ 1 author

8 November 2022

The pandemic of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed great threat to the world in many aspects. There is an urgent requirement for an effective preventive vaccine. The receptor binding domain (RBD), located...

(This article belongs to the Section Molecular Immunology)
  • Article
  • Open Access
31 Citations
7,132 Views
14 Pages

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape

  • Lin Yang,
  • Jiacheng Li,
  • Shuai Guo,
  • Chengyu Hou and ,
  • Chenchen Liao,
  • Liping Shi,
  • Xiaoliang Ma,
  • Shenda Jiang,
  • Bing Zheng and
  • Xiaodong He
  • + 7 authors+ 2 authors

9 November 2021

Since 2020, the receptor-binding domain (RBD) of the spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been constantly mutating, producing most of the notable missense mutations in the context of “variants of...

(This article belongs to the Collection Feature Papers in 'Macromolecules')
  • Article
  • Open Access
2,118 Views
29 Pages

Background/Objectives: The emergence of immune-evasive SARS-CoV-2 variants highlights the need for adaptable vaccine strategies. Trimeric receptor-binding domain (tRBD) antigens offer structural and immunological advantages over monomeric RBDs, but D...

(This article belongs to the Special Issue Cutting-Edge Approaches to Smart Pharmaceutics and Vaccine Development)
  • Article
  • Open Access
13 Citations
5,010 Views
14 Pages

Improved Expression of SARS-CoV-2 Spike RBD Using the Insect Cell-Baculovirus System

  • Joaquín Poodts,
  • Ignacio Smith,
  • Joaquín Manuel Birenbaum,
  • María Sol Rodriguez and ,
  • Luciano Montero,
  • Federico Javier Wolman,
  • Juan Ignacio Marfía,
  • Silvina Noemí Valdez,
  • Leonardo Gabriel Alonso and
  • María Victoria Miranda
  • + 6 authors+ 1 author

15 December 2022

Insect cell-baculovirus expression vector system is one of the most established platforms to produce biological products, and it plays a fundamental role in the context of COVID-19 emergency, providing recombinant proteins for treatment, diagnosis, a...

(This article belongs to the Special Issue Applications of Baculoviruses: Expression Factories, Vaccines and VLPs, Gene Delivery Vectors, Biological Control and Virus Genetics Models)
  • Article
  • Open Access
15 Citations
4,101 Views
18 Pages

Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein

  • Yu-Lei Chen,
  • Jin-Jin Lin,
  • Huan Ma,
  • Ning Zhong and ,
  • Xin-Xin Xie,
  • Yunru Yang,
  • Peiyi Zheng,
  • Ling-Jing Zhang,
  • Tengchuan Jin and
  • Min-Jie Cao
  • + 5 authors+ 0 author

18 September 2022

The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is the major target for antibody therapeutics. Shark-derived variable domains of new antigen receptors (VNARs) are the smallest antibody fragments with flexible paratopes that can reco...

(This article belongs to the Section Molecular Immunology)
  • Review
  • Open Access
6 Citations
11,768 Views
13 Pages

REM sleep behavior disorder (RBD) is a parasomnia in which the customary generalized skeletal muscle atonia of REM sleep, “REM-atonia”, is compromised, allowing for the injurious acting-out of dreams. RBD can be idiopathic/isolated (iRBD)...

(This article belongs to the Special Issue Sleep–Wake Medicine)
  • Article
  • Open Access
6 Citations
3,271 Views
25 Pages

Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies

  • Kanasap Kaewchim,
  • Kittirat Glab-ampai,
  • Kodchakorn Mahasongkram,
  • Thanatsaran Saenlom and ,
  • Watayagorn Thepsawat,
  • Monrat Chulanetra,
  • Kiattawee Choowongkomon,
  • Nitat Sookrung and
  • Wanpen Chaicumpa
  • + 4 authors+ 0 author

26 May 2023

Engineered nanobodies (VHs) to the SARS-CoV-2 receptor-binding domain (RBD) were generated using phage display technology. A recombinant Wuhan RBD served as bait in phage panning to fish out nanobody-displaying phages from a VH/VHH phage display libr...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Article
  • Open Access
1 Citations
3,254 Views
13 Pages

SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice

  • Ekaterina A. Volosnikova,
  • Iuliia A. Merkuleva,
  • Tatiana I. Esina,
  • Dmitry N. Shcherbakov and ,
  • Mariya B. Borgoyakova,
  • Anastasiya A. Isaeva,
  • Valentina S. Nesmeyanova,
  • Natalia V. Volkova,
  • Svetlana V. Belenkaya and
  • Elena D. Danilenko
  • + 12 authors+ 7 authors

6 April 2023

Despite the rapid development and approval of several COVID vaccines based on the full-length spike protein, there is a need for safe, potent, and high-volume vaccines. Considering the predominance of the production of neutralizing antibodies targeti...

(This article belongs to the Section Vaccine Design, Development, and Delivery)
  • Article
  • Open Access
3 Citations
3,161 Views
14 Pages

Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent

  • Yuanyuan Hu,
  • Caiqin Hu,
  • Shuo Wang,
  • Li Ren and ,
  • Yanling Hao,
  • Zheng Wang,
  • Ying Liu,
  • Junwei Su,
  • Biao Zhu and
  • Hao Liang
  • + 7 authors+ 2 authors

Since November 2021, Omicron has emerged as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, and its sublineages continue to appear one after another, significantly reducing the effectiveness of existing therapeutic...

  • Article
  • Open Access
11 Citations
3,633 Views
16 Pages

Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD

  • Antonia Sophia Peter,
  • Eva Grüner,
  • Eileen Socher,
  • Kirsten Fraedrich and ,
  • Elie Richel,
  • Sandra Mueller-Schmucker,
  • Arne Cordsmeier,
  • Armin Ensser,
  • Heinrich Sticht and
  • Klaus Überla
  • + 5 authors+ 0 author

Mutations in the spike protein of SARS-CoV-2 can lead to evasion from neutralizing antibodies and affect the efficacy of passive and active immunization strategies. Immunization of mice harboring an entire set of human immunoglobulin variable region...

(This article belongs to the Special Issue SARS-CoV-2 Variants, Antibodies and Vaccines)
  • Article
  • Open Access
1 Citations
3,263 Views
21 Pages

Study of Potential Blocking Peptides Targeting the SARS-CoV-2 RBD/hACE2 Interaction

  • Sara M. Villada-Troncoso,
  • Jenny Andrea Arévalo-Romero,
  • Vanessa Hernández Rivera,
  • Martha Pedraza-Escalona and ,
  • Sonia M. Pérez-Tapia,
  • Angela Johana Espejo-Mojica and
  • Carlos Javier Alméciga-Díaz
  • + 2 authors+ 0 author

20 September 2024

Background/Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, was declared a public health emergency in early 2020. The infection initiates when the receptor-binding domain (RBD) of the viral sp...

(This article belongs to the Section Biopharmaceuticals)
  • Article
  • Open Access
27 Citations
6,340 Views
12 Pages

Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants

  • Cong Liu,
  • Nino Rcheulishvili,
  • Zhigao Shen,
  • Dimitri Papukashvili and ,
  • Fengfei Xie,
  • Ziqian Wang,
  • Xingyun Wang,
  • Yunjiao He and
  • Peng George Wang
  • + 4 authors+ 0 author

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undoubtedly the most challenging pandemic in the current century and remains a global health emergency. As the number of COVID-19 cases in t...

(This article belongs to the Special Issue Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering)
  • Article
  • Open Access
2 Citations
3,741 Views
14 Pages

14 February 2023

The emergence of the recent pandemic causing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an alarming situation worldwide. It also prompted extensive research on drug repurposing to find a potential treatment for SARS-CoV-...

(This article belongs to the Special Issue State-of-the-Art Biophysics, Biochemistry and Molecular Biology in China)
  • Article
  • Open Access
12 Citations
4,948 Views
11 Pages

Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein

  • Junping Hong,
  • Qian Wang,
  • Qian Wu,
  • Junyu Chen and ,
  • Xijing Wang,
  • Yingbin Wang,
  • Yixin Chen and
  • Ningshao Xia
  • + 3 authors+ 0 author

To date, SARS-CoV-2 pandemic has caused more than 188 million infections and 4.06 million deaths worldwide. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein has been regarded as an important target for vaccine and therapeutics develo...

(This article belongs to the Collection Research on Monoclonal Antibodies and Antibody Engineering)
  • Communication
  • Open Access
11 Citations
11,907 Views
16 Pages

Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs

  • Enqing Tan,
  • Erica Frew,
  • Jeff Cooper,
  • John Humphrey and ,
  • Matthew Holden,
  • Amanda Restell Mand,
  • Jun Li,
  • Shaya Anderson,
  • Ming Bi and
  • Shelly Barry
  • + 9 authors+ 4 authors

Identifying anti-spike antibodies that exhibit strong neutralizing activity against current dominant circulating variants, and antibodies that are escaped by these variants, has important implications in the development of therapeutic and diagnostic...

(This article belongs to the Section Diagnostic Microbiology and Infectious Disease)
  • Communication
  • Open Access
5 Citations
2,971 Views
10 Pages

13 September 2022

In the context of the COVID-19 pandemic, conducting antibody testing and vaccination is critical. In particular, the continued evolution of SARS-CoV-2 raises concerns about the effectiveness of vaccines currently in use and the activity of neutralizi...

(This article belongs to the Special Issue RNA Viruses and Antibody Response)
  • Article
  • Open Access
10 Citations
4,811 Views
16 Pages

Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5

  • Zhantong Wang,
  • Baoshan Zhang,
  • Li Ou,
  • Qi Qiu and ,
  • Lingshu Wang,
  • Tatsiana Bylund,
  • Wing-Pui Kong,
  • Wei Shi,
  • Yaroslav Tsybovsky and
  • Peter D. Kwong
  • + 18 authors+ 13 authors

28 December 2023

The receptor-binding domain (RBD) of the SARS-CoV-2 spike is a primary target of neutralizing antibodies and a key component of licensed vaccines. Substantial mutations in RBD, however, enable current variants to escape immunogenicity generated by va...

(This article belongs to the Section COVID-19 Vaccines and Vaccination)
  • Article
  • Open Access
1 Citations
1,378 Views
14 Pages

A Poly-Lysine-Based RBD Mucosal Vaccine Induces Potent Antibody Responses in Mice

  • Huifang Xu,
  • Han Wang,
  • Peng Sun,
  • Tiantian Wang and ,
  • Bin Zhang,
  • Xuchen Hou,
  • Jun Wu and
  • Bo Liu
  • + 3 authors+ 0 author

(1) Background: The COVID-19 pandemic highlights the critical necessity for the development of mucosal vaccines. (2) Objective: In this study, we aimed to develop mucosal vaccines based on the receptor-binding domain (RBD) of the SARS-CoV-2 Spike pro...

  • Article
  • Open Access
2 Citations
1,861 Views
16 Pages

XBB.1.5 RBD-Based Bivalent Vaccines Induced Antibody Responses Against SARS-CoV-2 Variants in Mice

  • Jiawen Liu,
  • Tiantian Wang,
  • Hongying Ren,
  • Ruixi Liu and ,
  • Qian Wang,
  • Jun Wu and
  • Bo Liu
  • + 2 authors+ 0 author

(1) Background: The currently circulating variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits resistance to antibodies induced by vaccines. The World Health Organization recommended the use of monovalent XBB.1 sublineages...

(This article belongs to the Section COVID-19 Vaccines and Vaccination)
  • Article
  • Open Access
14 Citations
3,649 Views
13 Pages

Ginseng Polysaccharide Enhances the Humoral and Cellular Immune Responses to SARS-CoV-2 RBD Protein Subunit Vaccines

  • Jing Zhang,
  • Jing Feng,
  • Yang Huang,
  • Boyan Zhou and ,
  • Bing Li and
  • Rongxin Zhang
  • + 1 author+ 0 author

8 December 2023

The COVID-19 pandemic remarkably accelerated vaccine research progress. The role of adjuvants in enhancing vaccine immune intensity and influencing immune types has been considered. Ginseng polysaccharide (GPS) has been demonstrated to have strong im...

(This article belongs to the Section Vaccine Design, Development, and Delivery)
  • Article
  • Open Access
1 Citations
1,704 Views
12 Pages

Integrated In Silico and In Vivo Evaluation of a Tetravalent SARS-CoV-2 RBD–Fc Fusion Vaccine with Broad Cross-Variant Antibody Responses

  • Ahmad Bakur Mahmoud,
  • Renad M. Alhamawi,
  • Mustafa Yassin Taher,
  • Awadh S. Alsubhi and ,
  • Mekky M. Abouzied,
  • Heba M. Zahid,
  • Mohammed Abdullah Alotaibi,
  • Nada Almarghalani,
  • Khulood Alotaibi and
  • Almohanad Alkayyal
  • + 7 authors+ 2 authors

15 December 2025

Background/Objectives: SARS-CoV-2 continues to generate antigenically divergent variants that reduce the breadth of existing vaccine-induced antibody responses. Fc-fusion subunit vaccines offer advantages in stability, antigen display, and Fc-mediate...

(This article belongs to the Section COVID-19 Vaccines and Vaccination)
  • Article
  • Open Access
6 Citations
3,669 Views
11 Pages

An RBD-Based Diagnostic Method Useful for the Surveillance of Protective Immunity against SARS-CoV-2 in the Population

  • Dolores Adriana Ayón-Núñez,
  • Jacquelynne Cervantes-Torres,
  • Carlos Cabello-Gutiérrez,
  • Sergio Rosales-Mendoza and ,
  • Diana Rios-Valencia,
  • Leonor Huerta,
  • Raúl J. Bobes,
  • Julio César Carrero,
  • René Segura-Velázquez and
  • Juan Pedro Laclette
  • + 15 authors+ 10 authors

After more than two years, the COVID-19 pandemic is still ongoing and evolving all over the world; human herd immunity against SARS-CoV-2 increases either by infection or by unprecedented mass vaccination. A substantial change in population immunity...

(This article belongs to the Section Point-of-Care Diagnostics and Devices)
  • Article
  • Open Access
28 Citations
7,598 Views
12 Pages

Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages

  • Umesh Kalathiya,
  • Monikaben Padariya,
  • Robin Fahraeus,
  • Soumyananda Chakraborti and
  • Ted R. Hupp

17 February 2021

SARS-CoV-2, or COVID-19, has a devastating effect on our society, both in terms of quality of life and death rates; hence, there is an urgent need for developing safe and effective therapeutics against SARS-CoV-2. The most promising strategy to fight...

(This article belongs to the Special Issue Protein–Protein Interactions: Methods and Applications)
  • Article
  • Open Access

Intranasal Immunization with an E. coli-Expressed Omicron BA.5 RBD Elicits Systemic and Mucosal Immunity in Mice

  • Zelin Wang,
  • Mohammad Monirul Islam,
  • Mami Oba,
  • Tetsuya Mizutani and
  • Yutaka Kuroda
Molecules2026, 31(23), 4243;https://doi.org/10.3390/molecules31234243 
(registering DOI)

21 November 2026

SARS-CoV-2 infection occurs mainly through the respiratory tract; therefore, intranasal immunization represents a promising strategy for eliciting both systemic and mucosal immunity. In this study, we characterized an E. coli-expressed, non-glycosyla...

(This article belongs to the Special Issue Peptide and Protein Folding)
  • Article
  • Open Access
6 Citations
3,957 Views
25 Pages

Triterpene Derivatives as Potential Inhibitors of the RBD Spike Protein from SARS-CoV-2: An In Silico Approach

  • Mayra Avelar,
  • Laura Pedraza-González,
  • Adalgisa Sinicropi and
  • Virginia Flores-Morales

The appearance of a new coronavirus, SARS-CoV-2, in 2019 kicked off an international public health emergency. Although rapid progress in vaccination has reduced the number of deaths, the development of alternative treatments to overcome the disease i...

  • Article
  • Open Access
57 Citations
9,247 Views
16 Pages

Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2

  • Tuksin Jearanaiwitayakul,
  • Mathurin Seesen,
  • Runglawan Chawengkirttikul,
  • Jitra Limthongkul and ,
  • Suttikarn Apichirapokey,
  • Sompong Sapsutthipas,
  • Supaporn Phumiamorn,
  • Panya Sunintaboon and
  • Sukathida Ubol
  • + 4 authors+ 0 author

Mucosal immunity plays a significant role in host defense against viruses in the respiratory tract. Because the upper respiratory airway is a primary site of SARS-CoV-2 entry, immunization at the mucosa via the intranasal route could potentially lead...

(This article belongs to the Special Issue The COVID Vaccine)
  • Article
  • Open Access
4 Citations
3,336 Views
14 Pages

Enhanced Immunogenicity and Protective Effects against SARS-CoV-2 Following Immunization with a Recombinant RBD-IgG Chimeric Protein

  • Mariângela de Oliveira Silva,
  • Maria Fernanda Castro-Amarante,
  • Alexia Adrianne Venceslau-Carvalho,
  • Bianca da Silva Almeida and ,
  • Isabela Pazotti Daher,
  • Guilherme Antonio de Souza-Silva,
  • Marcio Massao Yamamoto,
  • Gabriela Koike,
  • Edmarcia Elisa de Souza and
  • Silvia Beatriz Boscardin
  • + 7 authors+ 2 authors

27 March 2024

The unprecedented global impact caused by SARS-CoV-2 imposed huge health and economic challenges, highlighting the urgent need for safe and effective vaccines. The receptor-binding domain (RBD) of SARS-CoV-2 is the major target for neutralizing antib...

  • Article
  • Open Access
6 Citations
4,025 Views
19 Pages

A CTB-SARS-CoV-2-ACE-2 RBD Mucosal Vaccine Protects Against Coronavirus Infection

  • Béla Dénes,
  • Ryan N. Fuller,
  • Wayne Kelin,
  • Tessa R. Levin and ,
  • Jaipuneet Gil,
  • Aaren Harewood,
  • Márta Lőrincz,
  • Nathan R. Wall,
  • Anthony F. Firek and
  • William H. R. Langridge
  • + 5 authors+ 0 author

18 December 2023

Mucosal vaccines protect against respiratory virus infection by stimulating the production of IgA antibodies that protect against virus invasion of the mucosal epithelium. In this study, a novel protein subunit mucosal vaccine was constructed for pro...

(This article belongs to the Topic Mucosal Immunity to Infectious Diseases)
  • Review
  • Open Access
2,001 Views
21 Pages

25 December 2025

REM sleep behavior disorder (RBD) represents a prodromal manifestation of Parkinson’s disease (PD), reflecting the breakdown of inhibitory networks extending from the brainstem to the cortex. This review synthesizes pathological, physiological,...

(This article belongs to the Section Applied Biosciences and Bioengineering)
  • Article
  • Open Access
3 Citations
2,671 Views
14 Pages

Dynamics of SARS-CoV-2 Spike RBD Protein Mutation and Pathogenicity Consequences in Indonesian Circulating Variants in 2020–2022

  • Nabiel Muhammad Haykal,
  • Fadilah Fadilah,
  • Beti Ernawati Dewi,
  • Linda Erlina and ,
  • Aisyah Fitriannisa Prawiningrum and
  • Badriul Hegar
  • + 1 author+ 0 author

14 November 2024

Background: Since the beginning of the coronavirus disease 2019 (COVID-19) outbreak, dynamic mutations in the receptor-binding domain (RBD) in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have altered the pathogenici...

(This article belongs to the Special Issue Bioinformatics of Human Diseases)
  • Communication
  • Open Access
21 Citations
5,677 Views
9 Pages

The rare but dangerous adverse events evidenced after massive vaccination against SARS-CoV-2 are represented by thrombosis and thrombocytopenia. The patients diagnosed with severe COVID-19 may develop a pro-thrombotic state with a much higher frequen...

(This article belongs to the Special Issue Coronavirus Disease (COVID-19): Pathophysiology)
  • Article
  • Open Access
3 Citations
2,761 Views
17 Pages

Increased Levels of Autoantibodies against ROS-Modified Proteins in Depressed Individuals with Decrease in Antibodies against SARS-CoV-2 Antigen (S1-RBD)

  • Subuhi Sherwani,
  • Mohamed Raafat,
  • Saravanan Rajendrasozhan,
  • Mahvish Khan and ,
  • Mohd Saleem,
  • Qayyum Husain,
  • Saif Khan,
  • Noor Alam and
  • Mohd Wajid Ali Khan
  • + 4 authors+ 0 author

28 October 2022

Coronavirus 2019 (COVID-19) disease management is highly dependent on the immune status of the infected individual. An increase in the incidence of depression has been observed during the ongoing COVID-19 pandemic. Autoantibodies against in vitro rea...

(This article belongs to the Special Issue Drug Development and Repositioning Methodology on COVID-19)
  • Article
  • Open Access
7 Citations
3,944 Views
17 Pages

Combination of Recombinant Proteins S1/N and RBD/N as Potential Vaccine Candidates

  • Noe Juvenal Mendoza-Ramírez,
  • Julio García-Cordero,
  • Sandra Paola Martínez-Frías,
  • Daniela Roa-Velázquez and ,
  • Rosendo Luria-Pérez,
  • José Bustos-Arriaga,
  • Jesús Hernández-Lopez,
  • Carlos Cabello-Gutiérrez,
  • Joaquín Alejandro Zúñiga-Ramos and
  • Leticia Cedillo-Barrón
  • + 8 authors+ 3 authors

18 April 2023

Despite all successful efforts to develop a COVID-19 vaccine, the need to evaluate alternative antigens to produce next-generation vaccines is imperative to target emerging variants. Thus, the second generation of COVID-19 vaccines employ more than o...

(This article belongs to the Special Issue Immune Responses to SARS-CoV-2 Infection and Vaccination)
  • Project Report
  • Open Access
7 Citations
4,333 Views
9 Pages

Utilization of Recombinant Baculovirus Expression System to Produce the RBD Domain of SARS-CoV-2 Spike Protein

  • Youpeng Fan,
  • Junhong Wei,
  • Wei Wang,
  • Chunfeng Li and ,
  • Guoqing Pan,
  • Timothy Keiffer,
  • Jialing Bao and
  • Zeyang Zhou
  • + 3 authors+ 0 author

Continuous outbreaks of viral diseases in humans facilitates a need for the rapid development of viral test kits and vaccines. These require expression systems to produce a pure and high yield of target viral proteins. We utilized a baculovirus&ndash...

  • Article
  • Open Access
80 Citations
12,919 Views
9 Pages

Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine

  • Bruna Lo Sasso,
  • Rosaria Vincenza Giglio,
  • Matteo Vidali,
  • Concetta Scazzone and ,
  • Giulia Bivona,
  • Caterina Maria Gambino,
  • Anna Maria Ciaccio,
  • Luisa Agnello and
  • Marcello Ciaccio
  • + 4 authors+ 0 author

(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection; (2) Methods...

(This article belongs to the Special Issue Biomarkers for Predicting Treatment Response and Guiding Therapy in COVID-19 Patients)
  • Article
  • Open Access
23 Citations
6,281 Views
12 Pages

6 January 2019

Middle East respiratory syndrome coronavirus (MERS-CoV) has continuously posed a threat to public health worldwide, yet no therapeutics or vaccines are currently available to prevent or treat MERS-CoV infection. We previously identified a fusion inhi...

(This article belongs to the Special Issue MERS-CoV)
  • Article
  • Open Access
3,306 Views
27 Pages

15 December 2022

To date, some succeeding variants of SARS-CoV-2 have become more contagious. This virus is known to enter human cells by binding the receptor-binding domain (RBD) of spike protein with the angiotensin-converting enzyme 2 (ACE2), the latter being a me...

(This article belongs to the Special Issue Design, Synthesis and Bioactivity Evaluation of Target-Based Antiviral Drugs)
  • Article
  • Open Access
674 Views
19 Pages

Dose-Dependent Influence of RBD-Derived Amyloidogenic Peptides on SARS-CoV-2 Infectivity: A Cautionary Tale for Antiviral Design

  • Maria A. Nikiforova,
  • Sergei Y. Grishin,
  • Anna Y. Aksenova,
  • Evgeniya I. Deryusheva and ,
  • Ilya V. Likhachev,
  • Roman S. Fadeev,
  • Margarita I. Kobyakova,
  • Alexey P. Kochetov,
  • Alexey K. Surin and
  • Oxana V. Galzitskaya
  • + 6 authors+ 1 author

The receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein remains a central target for antiviral drug development. Recent in silico studies have revealed an expansion of amyloidogenic regions within the RBD of the Omicron variant, raising the...

(This article belongs to the Collection Feature Papers in Molecular Microbiology)
  • Article
  • Open Access
10 Citations
3,005 Views
10 Pages

Antibodies to NCP, RBD and S2 SARS-CoV-2 in Vaccinated and Unvaccinated Healthcare Workers

  • Agata Błaszczuk,
  • Aleksander Michalski,
  • Maria Malm,
  • Bartłomiej Drop and
  • Małgorzata Polz-Dacewicz

22 July 2022

In a few months, the SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. In Poland, 6 million cases of the disease and 113,000 deaths from COVID-19 have been reported. Healthcare workers (HCWs) constitute one of the main COVID-19 risk groups. The...

(This article belongs to the Special Issue Cellular and Humoral Immunity after COVID-19 Vaccination)
  • Article
  • Open Access
33 Citations
10,412 Views
21 Pages

A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response

  • Duško Lainšček,
  • Tina Fink,
  • Vida Forstnerič,
  • Iva Hafner-Bratkovič and ,
  • Sara Orehek,
  • Žiga Strmšek,
  • Mateja Manček-Keber,
  • Peter Pečan,
  • Hana Esih and
  • Roman Jerala
  • + 23 authors+ 18 authors

27 April 2021

The response of the adaptive immune system is augmented by multimeric presentation of a specific antigen, resembling viral particles. Several vaccines have been designed based on natural or designed protein scaffolds, which exhibited a potent adaptiv...

(This article belongs to the Section COVID-19 Vaccines and Vaccination)
  • Article
  • Open Access
3 Citations
4,288 Views
18 Pages

Plant-Based Antigen Production Strategy for SARS-CoV-2 Nucleoprotein and RBD and Its Application for Detection of Antibody Responses in COVID-19 Patients

  • Katerina Takova,
  • Valeria Tonova,
  • Ivan Minkov,
  • Eugenia S. Mardanova and ,
  • Nikolai V. Ravin,
  • Stanislav Kotsev,
  • Maria Pishmisheva and
  • Gergana Zahmanova
  • + 3 authors+ 0 author

15 January 2025

During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the development of efficient serological tests for monitoring the dynamics of the disease as well as the immune response after illness or vaccination was critical. In t...

(This article belongs to the Section Chemical and Molecular Sciences)

of 29